Novo Holdings

Novo Holdings to Acquire Catalent for $16.5 Billion

Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said that Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Top-Feature

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Easyfairs Deutschland GmbH

Leading the way. Driving results.

JMP Statistical Discovery / SAS Institute GmbH

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Sasol

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Catalent Inc.

Novo Holdings

Novo Holdings to Acquire Catalent for $16.5 Billion

Top-Feature

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Leading the way. Driving results.

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Leading Transformation

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Anchored in Sustainability

Advanced Recycling Conference 2025: New Paths to the Circular Economy

API Manufacturing

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Brenntag Downsizes Management Board, Retains Both Divisions

Expert Insights

Dual‑Targeting Breakthroughs

Newsletter & e-edition